125 filings
Page 3 of 7
6-K
vtb5th hz
30 Apr 20
CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma
4:07pm
6-K
vel he41ilqwy2xo7
14 Apr 20
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020
9:48am
6-K
j2z7jt69h
1 Apr 20
Current report (foreign)
5:07pm
6-K
6fgzbqkjtqrkcno
1 Apr 20
Current report (foreign)
10:29am
6-K
ep5nsr
31 Mar 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
4:00pm
6-K
21vx xk2s8bje4u
31 Mar 20
Current report (foreign)
9:38am
20-F
q8fu szfjpabzb6n8pv
30 Mar 20
Annual report (foreign)
5:12pm
6-K
85953w kcpnsv8q
26 Mar 20
Current report (foreign)
5:12pm
6-K
dej26ygol7szd38k
26 Mar 20
Passing of Genmab A/S’ Annual General Meeting
12:03pm
6-K
d4nius ak
24 Mar 20
Genmab A/S Provides Update to Annual General Meeting
12:58pm
6-K
bt0t7q98l 6hn6sp
10 Mar 20
Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer
9:17am
6-K
tgk xyd2xlzgu
27 Feb 20
Notice to Convene the Annual General Meeting of Genmab A/S
3:48pm
6-K
11u3zxwrqq3 w65v
26 Feb 20
Current report (foreign)
2:17pm
6-K
5pj1j44djxoz39
26 Feb 20
Current report (foreign)
12:46pm
6-K
wa4jdgsysag457myd
25 Feb 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
5:19pm
6-K
jnz75hivt43gqernp
21 Feb 20
Current report (foreign)
4:40pm
6-K
tfpcpg9v w8lgz5
19 Feb 20
Innovating antibodies, improving lives Annual Report 2019 Genmab A/S CVR No. 21 02 38 84
1:28pm
SC 13G
3blmb9 05bugordn
7 Feb 20
Beneficial ownership report
8:55am
6-K
k2o3wt o0
22 Jan 20
Genmab to receive milestone payment of USD 150 million in DARZALEX collaboration
9:09am
6-K
73jzqc5oypqx
21 Jan 20
Current report (foreign)
8:56am